文献速递精神分裂症与精神病性障碍

呫诺美林/曲司氯铵治疗精神分裂症的52周开放标签扩展试验

Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.
PubMed 文献 · Am J Psychiatry · 2026-02-04

EMERGENT-4为52周开放标签扩展试验,纳入完成EMERGENT-2或EMERGENT-3的152例精神分裂症成人患者,评估呫诺美林/曲司氯铵(X/T)长期安全性、耐受性和疗效。结果显示53.3%的受试者出现至少1例治疗中出现的不良事件(TEAE),最常见为轻中度胃肠道反应,无新的安全性问题,PANSS总分持续改善。

要点

  • 52周X/T治疗总体安全、耐受性良好,最常见不良事件为轻中度胃肠道反应。
  • 未见有临床意义的运动症状、高催乳素血症、体重增加或代谢参数不良影响。
  • PANSS总分、CGI-S及阳性/阴性亚量表评分在试验期间持续改善。

核心结论

  • 52周X/T长期治疗在精神分裂症患者中安全、总体耐受性良好,并与持续的症状改善相关。

研究设计与样本

  • EMERGENT-4为52周开放标签扩展试验,纳入完成EMERGENT-2和EMERGENT-3急性期试验的受试者。
  • 主要终点为报告治疗中出现的不良事件(TEAE)的受试者比例。

主要发现

  • 366例完成EMERGENT-2或EMERGENT-3的受试者中156例(42.6%)入组EMERGENT-4,其中34例(21.8%)完成52周治疗期。
  • 152例接受治疗的受试者中81例(53.3%)出现至少1例TEAE。
  • 最常见的治疗相关不良事件为胃肠道疾病(如恶心、呕吐、消化不良、口干),多为轻中度,继续治疗可缓解。
  • 未观察到新的安全性或耐受性问题,未见有临床意义的运动症状、高催乳素血症、体重增加或代谢参数不良影响。
  • PANSS总分从急性期试验基线至第52周的平均变化:急性期接受X/T组为-33.8,急性期接受安慰剂组为-31.3;CGI-S、PANSS阳性亚量表和阴性亚量表呈类似持续改善模式。

关键数值与推荐

  • 主要终点:报告TEAE的受试者比例为81/152(53.3%)。
  • 入组情况:156/366(42.6%)入组EMERGENT-4;34/156(21.8%)完成52周治疗期。
  • PANSS总分从急性期基线至第52周平均变化:X/T组-33.8,安慰剂组-31.3。

临床怎么用

  • 对于已完成急性期X/T治疗的精神分裂症患者,可考虑继续长期使用X/T,治疗期间关注胃肠道不良反应并对症处理。
  • 长期用药中可监测运动症状、催乳素、体重及代谢参数,但本试验未提示有临床意义的不良影响。

局限性

  • 为开放标签扩展试验,无对照,疗效与安全性解释需谨慎。
  • 完成52周治疗期的受试者仅34例(21.8%),长期数据代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Xanomeline and trospium chloride (X/T) reduced symptoms and was generally well tolerated in two phase 3, 5-week, randomized, double-blind, placebo-controlled trials in adults with schizophrenia. The authors evaluated the long-term safety, tolerability, and efficacy of X/T in an open-label extension of the two phase 3 trials. METHODS: EMERGENT-4 was a 52-week open-label extension trial of participants who completed the EMERGENT-2 and EMERGENT-3 acute trials. Between February 2021 and October 2023, 152 participants initiated twice-daily oral doses of xanomeline 50 mg/trospium 20 mg and titrated to a maximum dosage of twice-daily oral xanomeline 125 mg/trospium 30 mg. The primary endpoint was the proportion of participants reporting a treatment-emergent adverse event (TEAE). Efficacy measures included Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impressions severity scale (CGI-S). RESULTS: A total of 156 (42.6%) of the 366 participants who completed EMERGENT-2 or EMERGENT-3 enrolled in EMERGENT-4; of these 34 (21.8%) enrolled participants completed the 52-week treatment period. Overall, 81 (53.3%) of 152 treated participants experienced at least one TEAE. Consistent with the acute trials, the most common treatment-related adverse events were gastrointestinal disorders (e.g., nausea, vomiting, dyspepsia, dry mouth) that were mild or moderate in intensity and resolved with continued treatment. No new safety or tolerability issues were observed. X/T was not associated with clinically meaningful motor symptoms, hyperprolactinemia, weight gain, or adverse effects on metabolic parameters. X/T was associated with continued symptom improvement over the trial duration. Mean changes in PANSS total score from acute trial baseline to week 52 were -33.8 and -31.3 in the treatment groups receiving X/T and placebo, respectively, in the acute trials. Similar patterns of continued improvement were observed for scores on the CGI-S, PANSS positive subscale, and PANSS negative subscale. CONCLUSIONS: Long-term treatment with X/T over 52 weeks was safe, generally well tolerated, and associated with durable symptom improvement in people with schizophrenia.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kaul I, Claxton A, Sauder C, et al. Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. Am J Psychiatry. 2026. PMID: 41634905. doi:10.1176/appi.ajp.20241186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。